Search results

...pamil]], [[nifedipine]], [[simvastatin]], [[midazolam]] and [[HIV protease inhibitors]]. Other possible interactions include [[antiretroviral agents]], [[everoli {{Nucleic acid inhibitors}}

...nosine]] and [[zalcitabine]]. HIV strains that are resistant to [[protease inhibitors]] are not likely to be resistant to abacavir. [[Category:Nucleoside analog reverse transcriptase inhibitors]]

...approval process switched to [[protease inhibitor (pharmacology)|protease inhibitors]]. According to the manufacturer's 2004 annual report, its patent will expi [[Category:Nucleoside analog reverse transcriptase inhibitors]]

...]], efavirenz has been used as first line treatment in preference to the [[protease inhibitor]]s. The [[ACTG 5095]] trial showed that the potency of efavirenz ...ase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors | journal=Proc Natl Acad Sci USA | volume=99 | pages=14410–15 | pmid=1238

...ase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors |journal=Proc Natl Acad Sci USA. |volume=99 |issue=22 |pages=14410–5 |yea ...randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients | journal=AIDS | volume=17 |issue=7 |

...actured by [[Merck & Co.|Merck]]) is a [[protease inhibitor (pharmacology)|protease inhibitor]] used as a component of [[antiretroviral drug|highly active anti ...r on design and introduction of subsequent antiretroviral drugs. Protease inhibitors changed the very nature of the AIDS epidemic from one of a terminal illness

...etroviral drug|antiretroviral]] of the [[Protease inhibitor (pharmacology)|protease inhibitor]] class. It is marketed by [[Abbott Laboratories|Abbott]] as '''K ...navir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent

...is an [[antiretroviral drug]] from the [[protease inhibitor (pharmacology)|protease inhibitor]] class used to treat [[HIV]] infection and [[AIDS]]. ...n, but as it inhibits the same host enzyme that metabolizes other protease inhibitors. This inhibition leads to higher plasma concentrations of these latter drug

...ed in [[HIV]] therapy. It falls in the [[protease inhibitor (pharmacology)|protease inhibitor]] class. Two formulations have been marketed: Saquinavir was the first protease inhibitor (and sixth antiretroviral) approved by the [[Food and Drug Admini

...o the class of drugs known as [[protease inhibitor (pharmacology)|protease inhibitors]] (PIs) and like other PIs is generally used in combination with other anti ...t al.'' |title=Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma

=====Nucleoside/nucleotide reverse transcriptase inhibitors===== =====Non-nucleoside reverse transcriptase inhibitors=====

...urnal | author=De Clercq E | title=HIV resistance to reverse transcriptase inhibitors. | journal=Biochem Pharmacol | volume=47 | issue=2 | pages=155–69 | year= ...r a [[Reverse transcriptase inhibitor#Non-nucleoside reverse transcriptase inhibitors (NNRTIs)|non-nucleoside reverse transcriptase inhibitor]], this type of the

...itors (NtRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), [[protease inhibitor]]s (PIs), and a single [[fusion inhibitor]]. PEP anti-HIV regimen